MAGEA3 and non-small cell lung carcinoma: The therapeutic vaccine trials in our analysis targeted patients with varying stages of non-small cell lung cancer (NSCLC), including stage IB, II, and IIIA MAGE-A3-positive tumors, unresectable stage III, and stage IIIb/IV NSCLC.